SCHEMBL1661737

SCHEMBL1661737

CCn1nc(Oc2ccc(F)cc2N)cc1-c1cccc(C#N)c1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
GABRG2 P18507 4/20 0.37
GABRB3 P28472 4/20 0.37
GABRA5 P31644 4/20 0.37
GABRA3 P34903 4/20 0.37
PDE4D Q08499 3/20 0.36
KCNK3 O14649 2/20 0.35
ADORA2B P29275 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
NR3C1 P04150 1/20 0.34
NR3C2 P08235 1/20 0.34
PARP1 P09874 1/20 0.34
PARP3 Q9Y6F1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1659890 0.84 GABRG2 (0.40) SCN9ACYP11B1CYP11B2GABRG2GABRB3
SCHEMBL1658685 0.84 MEN1 (0.43) SCN9ACYP11B1CYP11B2KCNK3
SCHEMBL1659906 0.83 GABRG2 (0.39) SCN9AGABRG2GABRB3GABRA5GABRA3
SCHEMBL1659949 0.75 SCN9A (0.42) SCN9AGABRG2GABRB3GABRA5GABRA3
SCHEMBL5387429 0.73 PTGS1 (0.45) SCN9ACYP11B1CYP11B2GABRG2GABRB3
SCHEMBL5394734 0.73 CYP11B1 (0.42) CYP11B1CYP11B2GABRG2GABRB3GABRA5
SCHEMBL890912 0.71 EPAS1 (0.46)
SCHEMBL5386649 0.69 NOTUM (0.45) CYP11B2GABRG2GABRB3GABRA5GABRA3
SCHEMBL5391491 0.69 GABRG2 (0.41) CYP11B1CYP11B2GABRG2GABRB3GABRA5
SCHEMBL1660602 0.68 GABRG2 (0.42) SCN9AGABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871796-B2 Diaryl ether derivatives as notch sparing gamma secretase inhibitors MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-8871796-B2 Diaryl ether derivatives as notch sparing gamma secretase inhibitors MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-20130053386-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME LLC 2013-02-28 US disclosed
US-20130053386-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME LLC 2013-02-28 US disclosed
EP-2488031-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-08-22 EP disclosed
WO-2011046774-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053386-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS BACE1, BACE2, GSAP SCN9A 1887/4885CYP11B1 1011/4885CYP11B2 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.